Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $1.2 million.

  • GeneDx Holdings' Gains from Investment Securities rose 3159.09% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 6655.0%. This contributed to the annual value of $13.4 million for FY2024, which is 27159.53% up from last year.
  • According to the latest figures from Q3 2025, GeneDx Holdings' Gains from Investment Securities is $1.2 million, which was up 3159.09% from $62000.0 recorded in Q2 2025.
  • GeneDx Holdings' 5-year Gains from Investment Securities high stood at $81.7 million for Q3 2021, and its period low was -$76.2 million during Q4 2021.
  • Moreover, its 5-year median value for Gains from Investment Securities was $895500.0 (2023), whereas its average is -$3.3 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 29794.56% in 2021, then soared by 29762.44% in 2024.
  • GeneDx Holdings' Gains from Investment Securities (Quarter) stood at -$76.2 million in 2021, then soared by 79.17% to -$15.9 million in 2022, then soared by 109.23% to $1.5 million in 2023, then surged by 35.15% to $2.0 million in 2024, then plummeted by 41.52% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $62000.0 for Q2 2025, and $1.1 million during Q1 2025.